IFNG and neoplasm: A fusion protein between tumor necrosis-targeting human IgG1 NHS76 and IL-12 (NHS-IL12) had longer half-life in vivo, stimulated lower IFN-γ release by immune cells thereby limiting the IL-12 mediated toxicity, and had superior antitumor efficacy in mouse models (173).